You are here

Home » Content

KARDİYOVASKÜLER İLAÇLAR VE DERMATOLOJİK YAN ETKİLERİ

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Cutaneous adverse effects of cardiovasculary medicaments take an important place among the side effects of these medicaments and may be seen 1-19 % due to the used drug. Pruritus, oedema, vasculitis, thrombositopenic purpura, macule, papule, erythema, blisters, urticaria, angioneurotic oedema are common symptoms and diseases. Photosensitivity, hyperpigmentation, erythema multiforme and alopecias may be seen infrequently. Otherwise, there are some special uncommon symptoms which have been seen related with certain medicaments. Acecanide, disopramide, procainamide, propaphenone, quinidine, acebutolol, furosemide, clonidine and reserpine may cause Lupus erythematosus-like dermatitis. Atenolol, carvedilol, practolol, may cause psoriasiform reactions. Captopril, hydrochlorothiaside, aspirine may cause pityriasis rosea like dermatitis, enalapril may cause to pemphigus and diazoxide may cause to hypertrichosis.
Bookmark/Search this post with
Abstract (Original Language): 
Kardiyovasküler ilaçların yan etkileri arasında, dermatolojik yan etkiler önemli bir yer tutmaktadır. Kullanılan ilaçlara göre bu oran % 1-19 arasında değişmektedir. Genel olarak yan etkiler arasında kaşıntı, ödem, vaskülitler, trombositopenik pupura, makül, papül, bazen büller şeklinde lezyonlar, ürtiker, anjiyoödem sık görülen belirtilerdir. Fotosensitivite, hiperpigmentasyon, eritem polimorf, alopesiler daha az görülür. Ayrıca bazı ilaçlar özel belirtiler gösterebilmektedir. Acecainide, procainamide, propaphenone, quinidine, acebutalol, atenolol, furocemide, clonidine ve reserpine ile "Lupus Eritematodes Benzeri", atenolol, carvedilol, labetolol, practolol ile "Psoriasis Benzeri", Kaptopril, hydrochlorothiaside ile "Likenoid Tipte" belirtiler görülebilir. Kaptopril, chlonidine ve aspirin ile "Pitriyasis Rosea Benzeri" belirti, enalapril ile "Pemphigus" ve digoxide ile de "Hypertrichosis" görülebilir.
FULL TEXT (PDF): 
PDF icon arastirmax-kardiyovaskuler-ilaclar-dermatolojik-yan-etkileri.pdf
  • 4
286-297
  • Turkish

REFERENCES

References: 

1. Kluger J, Drayer DE, Redenberg MM, Lahita R. Acetylprocainamide therapy in patients with previous procainamide-induced lupus. Ann Intern Med 1981; 95: 18-23.
2. Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Antiarrythmic efficacy, pharmacokinetics and safety of N- acetylprocinamide in human subjects. Comparison with procainamide. Am J Cardiol 1980; 46: 463-468.
3. Atkinson AJ. Lertora JJL. Kushner W, Chao GC, Nevin MJ. Efficacy and safety of N- acetylprocainamide in long-term treatment of ventricular arrhythmias. Clin Pharm Ther 1983; 33: 565-576.
4. Lertora JJL. Atkinson AJ Jr. Kushner W, Nevin MJ, Lee WK, Jones C, Schmid FR. Long term antiarrythmic therapy with N-acetylprocainamide. 1979; 25: 273-282.
5. Medical Economics Co. Montvale, NJ. Physicians' Desk Reference 1996.
6. Mancuso G,Tampieri E, Berdondini RM. Psoriasis-like eruption caused by flecainide. G Ital Dermatol Venereol 1988; 123: 171-172.
7. Palace J, Shah R, Clough C. Flecainide induced peripheral neuropathy. Br Med J 1992; 305: 810.
8. Bricker SR, Raitt DG. Angioneurotic edema following etomidatelignocaine. Anaesthesia 1987; 42: 323-324.
9. Black RJ, Dawson TA, Strang WC. Contact sensitivity to lignocaine and prilocaine. Contact Dermatitis 1990; 23:117-118.
10. Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988; 18: 721-741.
11. Vivard I, Trechot P, Schmutz JL,Cuny JF, Weber M, Beurey J. Phenytoin and hirsutism. Ann Dermatol Venereol 1989; 116: 562.
12. Kleier RS, Sreneman DL, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991; 27:1361-1364.
13. Rowe JE, Pina J, Sau P, James W. Toxic epidermal necrolysis associated with diphenylhydantoin and cranial irradiation. Int J Dermatol 1991; 30: 747-749.
14. Kelly DR, Hope DG. Fatal phenytoin-related toxic epidermal necrolysis. Case report. Neurosurgery 1989; 25: 976-978.
15. Gately LE, Lam M. Phenytoin-induced toxic epidermal necrolysis. Ann Intern Med 1979; 91: 59-60.
16. Schreiber MM, McGregor JG. Pseudolymphoma sydrome: Asensitivity to Anticonvulsant drugs. Arch Dermatol 1968; 97: 297-300.
17. Norris JF, Cunliffe WJ.Phenytoin-induced gum hypertrophy improved by isoretinoin. Int J Dermatol 1967; 26:602-603.
18. McLoughlin P, Newman L, Brown A. Oral squamous cell carcinoma arising in phenytoin-induced hyperplasia. Br Dent J 1995; 178: 183-184.
19. MacDonal E, Marino C. Procainamide-induced lupus in the elderly. Hosp Pract (Office ed.) 1993; 228: 95-98.
20. Knox JP, WelykyJ SE, Granidi R, Massa MC. Procainamide-induced urticarial vasculitis. Cutis 1988; 42:51-53.
21. Guindo J, Rodriguez A, Borja J. Propafenone and a syndrome of the lupus erythematosus type. Ann Intern Med 1986; 104:589.
22. Pariser DM, Taylor JR. Quinidine photosensitivity. Arch Dermatol 1975; 111: 1440-1443.
23. Taylor DR, Potashnick R. Quinidine-induced exfoliative dermatitis. JAMA 1951; 145: 641-642.
24. Nudelman PL, Leff IL, Howe CD. Thrombocytopenic purpura following quinidine. JAMA 1948; 137: 1219-1220.
25. Arrowsmith JB, Creamer JI, Bosco L. Severe dermatologic reactions reported after treatment with tocainide. Ann Intern Med 1987; 107: 693-696.
26. Dunn JM, Groth PE, DeSimone A. Tocainidine: A severe adverse reaction. Drug intell Clin Pharm 1988; 22: 142-145.
27. Duff HJ, Roden DM, Marney S, Colley DG, Maffucci R, Primm RK, Oates JA, Woosley RL. Molecular basis for the antigenicity of lidocaine analogs: Tocainide and mexilitine. Am Heaart J 1984; 107: 585-589.
28. Cody RJ, Calabrese LH, Clough JD, Tarazi RC, Bravo EL. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 1979; 25: 800-805.
29. Wolf R, Ophir J, Elman M, Krakowski A: Atenolol-induced cutaneous vasculitis. Cutis 1989; 443: 231-233.
30. Goral R, Dorman TL, Ledingham JGG: Peripheral skin necrosis complicating beta blockage. Br Med J 1979; 1: 721-722.
31. Staughton R, Sutton R, Farrel M: Beta blockers, autoimmunity and rashes. Lancet 1980: 2: 581.
32. Almedya J, Levantine A. Cutaneous reactions to cardiovascular drugs. Br J Derm 1973; 88: 313-319.
33. Grance RW, Jones EW. Bullous lichen planus caused by labetalol. Br Med J 1979; 2: 496-497.
34. Neumann Ham, Van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor blocking agents. Dermatologica 1981; 162: 330-335.
35. Leonard JC. Oxprenolol and a psoriasis-like eruption. Lancet 1975; 1:6 30.
36. Harrower ADB, Strong JA. Hyperpigmentation associated with oxprenolol. Br Med J 1975; 2: 539-540.
37. Holt PJA, Waddington E. Oculocutaneous reaction to oxprenolol. Br Med J 1975; 2: 539-540.
38. Waal-Manning HJ. Problems with practolol. Drugs 1975; 10: 336-341.
39. Hu CH, Peppercorn R, Farber EM. Generalized pustular psoriasis provoked by propranolol. Arch Dermatol 1985; 212: 1326-1327.
40. Mukul VG, Verma G. Propranolol-induced Stevens-Johnson syndrome from maprotiline and propranolol. 1989; Assoc Phys India 37: 797-798.
41. O'Brien TJ, Lvam IG, Reid SS. Lichenoid eruption by sotalol. Aaustralas J Dermatol 1994; 35: 93-94.
42. Rappersberger K, Honigsmann H, Ortel B, Tanew A, Konrad K, Wolff KJ. Photosensivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. Invest Dermatol 1989; 93: 201-209.
43. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 121-158.
44. Feigi D, Gilard R, Kaatz E. Complications of low-dose amiodarone. 1991; 121: 374-377.
45. Reifler DM, Vedier DD, Davy CL. Multiple chalazia and rosacea in a patient treated with amiodarone. Am J Ophthalmol 1987; 103: 594-595.
46. Staubi M Zimmermann A, Bircher J. Amiodarone-induced vasculitis and polyserositis. Postgrad Med J 1985; 61: 245-247.
47. Porters JE, Zantkuyl CF. Ioderma caused by amiodarone. Arch Dermatol 1975; 111: 1656.
48. Khanderia U, Jaffe CA, Theisen V. Amiodarone-induced thyroid dysfunction. Clin Pharm 1993: 2; 774-779.
49. Trif MD, Wiersinga W,Plomp TA. İncidence, predictability, and patogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991: 91; 507-511.
50. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991: 170; 376-379.
51. Seymour RA, Ellis JS, Thomason JM. Amlodipin-induced gingival over growth. J Clin Periodontol 1994: 21; 281-283.
52. Dacosta A, Mismetti P, Tardy B. Non-thrombopenic purpura induced by amlodipine. Therapie 1994; 49: 515-517.
53. Janier M Gerault MH, Carlotti A, Vignon MD, Daniel F. Acute generalized exanthematous pustulosis due to diltiazem. Br J Dermatol 1993; 129: 354-355.
54. Sanders CJ, Neumann HA. Erythema multiforme, Stevens-Johnson syndrome, and diltiazem. Lancet 1993; 341: 967.
55. Reynolds NJ, Jones SK, Crossley J, Harman RR. Exfoliative dermatitis due to nifedipine. Br J Dermatol 1989; 121: 401-404.
56. Kürkçüoğlu N, Alaybeyi F. Erythema multiforme after verapamil treatment. J Am Acad Dermatol 1991; 24: 511-512.
57. Griffth MJ, Ward DE, Linker NJ, Camm AJ. Adenosine in the diagnosis of broad complex tachycardia. Lancet 1988; 1: 672-675.
58. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, Dimarca JP. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988; 61: 336-340.
59. David M, Livni E, Stern E, Feuerman EJ, Grinblatt J. Psoriasiform eruption induced by digoxin: confirmed by re-exposure. J Am Acad Dermatol 1981; 5: 702-703.
60. Chu TJ, Crow N. Adverse effects of ACE inhibitors. Ann Intern Med 1993; 118: 314-315.
61. Kaplan RP, Potter TS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1992; 26; 364-366.
62. Bertin P, Kamdem J, Bonneet C. Captopril-induced lupus. Clin Exp Rheumatol 1993; 11: 695.
63. Larbre JP, Nicolas JF, Collet P, Larbre B, Liorca G. Kaposi's sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol 1991; 18: 476-477.
64. Llop R, Gomez- Farran F, Figueras A. Gynecomastia associated with enalapril and diazepam. Ann Pharmacother 1994; 28: 671-672.
65. Shelton RM. Pemphigus foliaceous associated with enalapril. J Am Acad Dermatol 1991: 24; 503-504.
66. Bielory L, Lee SS, Holland CL, Jaker M. Long-acting ACE-inhibitor angioedema. Aller Proc 1992; 13: 85-87.
67. Rees RS, Bergman J, Ramirez-Alexander R. Angioedema associated with lisinopril. Am J Emerg Med 1992; 10: 321-322.
68. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995; 333: 1572.
69. Cernek PK. Dermal cellulitis-a hypersensitivity reaction from dobutamine hydrochloride. 1994: 28; 964.
70. Bork K. Cutaneous Side Effects of Drugs. Philadelphia, WB Saunders Co, 1988; 3-18.
71. McCauley WA, Gerace RV, Scilley C. Treatment of accidental digital injection of epinephrine. Ann Emerg Med 1991: 20; 665-668.
72. Gibson TP, Blue P. Erythema multiforme and furosemide therapy. JAMA 1970; 212: 1709.
73. Fellner MJ, Katz JM. Occurence of bullous pemphgoid after furosemide therapy. Arch Dermatol 1976; 122: 75-77.
74. Wollenberg A, Meurer M. Thiazide diuretic-induced subacute cutaneous lupus erythematosus. Hautarzt 1991; 42: 709-712.
75. Biornberg A, Gisslen H. Thiazides: A cause of necrotizing vasculitis? Lancet 1965; 2: 982-983.
76. Danby FW. Spironolactone. J Am Acad Dermatol 1992; 26: 137.
77. Baume P, Ratcliffe FJ, Corry JR: Triamterene, a new natriuretic agent. Am J Med Sci 1963; 245: 668-675.
78. Witman G, Davis R. A lupus erythematosus syndrome induced by clonidine hydrochloride. RI Med J 1980; 102: 147-150.
79. Kuan P. Dangers of diazoxide. Br Med J 1973; I: 114.
80. Yonga GD. Low dose hydralazine induced lupus. East Afr Med J 1992; 69: 649-650.
81. Peterson II. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984; 10: 379-380.
82. Vaillant L, Le Maarchand D, Grognard C, Hocine R, Lorette G. Photosensitivity to methyldopa. Arch Dermatol 1988: 124; 326-327.
83. Wells JD, Kurtay M, Lochner JC. Granulomatouus skin lesions and alpha-methyl dopa. Ann Intern Med 1974: 81; 701-702.
84. Burton JL, Marchall A. Hyperthrichosis due to minoxidil. Br J Dermatol 1979; 101: 593-595.
85. DiSantis DJ, Flanagan J. Minoxidil-induced Stevens-Johnson syndrome. Arch Intern Med 1981; 141: 1515.
86. De La Fuente Prieto R, Armentia Medina A, Diez Perez JM. Contact dermatitis from nitroglycerin. Ann Allergy 1994; 72: 344-346.
87. Baker H, Moore-Robinson M. Cutaneous responses to aspirin and its derivatives. Br J Dermatol 1970; 82: 319-321.
88. Brannen M, Forbes AF. Salicylate sensitivity. Tex J Med 1966; 62: 58-60.
89. Shelley WB. Birch pollen and aspirin psoriasis. JAMA 1964; 189: 985-988.
90. Phillips DE, Payne DK, Millis GM. Heparin induced thrombotic thrombocytopenia Ann Pharmacother 1994; 28: 43-46.
91. Kelly RA, Gelfand JA,Pincus SH. Cutaneous necrosis caused by sytemically administered heparin. JAMA 1981; 246: 1582-1583.
92. Gold JA, Watters AK, O'Brien E. Coumadin versus heparin necrosis. J Am Acad Dermatol 1987;16: 148-149.
93. Real E, Grau E, Rubio M, Torrecilla T. Skin necrosis after subcutaneous low molecular weight heparin injection. Am J Haematol 1995; 49: 253-254.
94. Ojeda, E, Perez MC, Mataix R, Arbelo A, Jimenez S, Campo C, Balda I. Skin necrosis with a low molecular weight heparin. Br J Haematol 1992; 82: 620.
95. Humpries JE, Kaplan DM, Bolton WK. Heparin skin necrosis: delayed occurrence in a patient on hemodialysis. Am J Kidney Dis 1991; 17: 233-236.
96. Bircher AJ, Itin PH, Buchner SA. Skin lesions, hypereosinophilia, and subcutaneous heparin. Lancet 1994; 342: 1371.
97. Sternberg MC, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med 1995; 26: 94-97.
98. Baker H, Levene GM. Cutaneous reactions to anticoagulants. Br J Dermatol 1969; 81: 236-238.
99. Wong SS. Stevens-Johnson syndrome induced by clofibrate. Acta Derm Venereol 1994; 74: 475.
100. Smith GW, Hurst NP. Vasculitis, Raynaud's phenomenon, and polyarthritis associated with gemfibrozil therapy. Br J Rheum 1993; 32: 84-85.
101. Ahmed S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991; 151: 1667-1668.
102. Stals H, Vercammen C, Peeters C. Morren MA. Acanthosis nigracans caused by nicotinic acid: Case report and review of the literature. Dermatology 1994; 189: 203-206.
103. Charman RC, Matthews LB, Braculer C. Nicotinic acid in the treatment of hypercholesterolemia. Angiology 1972; 23: 29-35.

Thank you for copying data from http://www.arastirmax.com